Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
106M
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
69.5M
-
Shares change
-
-1.17M
-
Total reported value, excl. options
-
$904M
-
Value change
-
-$23.1M
-
Put/Call ratio
-
1.76
-
Number of buys
-
86
-
Number of sells
-
-43
-
Price
-
$13.01
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q2 2024
164 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q2 2024.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.5M shares
of 106M outstanding shares and own 65.66% of the company stock.
Largest 10 shareholders include FMR LLC (9.57M shares), BlackRock Inc. (4.77M shares), Deep Track Capital, LP (3.92M shares), VR Adviser, LLC (3.88M shares), VANGUARD GROUP INC (3.35M shares), MAVERICK CAPITAL LTD (3.31M shares), Paradigm Biocapital Advisors LP (2.9M shares), STATE STREET CORP (2.77M shares), COMMODORE CAPITAL LP (2.53M shares), and Novo Holdings A/S (2M shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.